These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17283166)

  • 1. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
    Chen A; Liu S; Park D; Kang Y; Zheng G
    Cancer Res; 2007 Feb; 67(3):1291-8. PubMed ID: 17283166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
    He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
    Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells.
    Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N
    Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
    Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
    Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
    Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
    Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
    Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
    Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfusion of ex vivo donor alloantigen-stimulated CD4(+)CD25(+) regulatory T cells ameliorates rejection of DA-to-Lewis rat liver transplantation.
    Pu LY; Wang XH; Zhang F; Li XC; Yao AH; Yu Y; Lv L; Li GQ
    Surgery; 2007 Jul; 142(1):67-73. PubMed ID: 17630002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of CD4+CD25+Foxp3+ regulatory T cells in aged Balb/c mice.
    Zhao L; Sun L; Wang H; Ma H; Liu G; Zhao Y
    J Leukoc Biol; 2007 Jun; 81(6):1386-94. PubMed ID: 17369496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells.
    Brandenburg S; Takahashi T; de la Rosa M; Janke M; Karsten G; Muzzulini T; Orinska Z; Bulfone-Paus S; Scheffold A
    Eur J Immunol; 2008 Jun; 38(6):1643-53. PubMed ID: 18493984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination of CD4+ CD25+ regulatory T cell and costimulatory pathway blockade inhibits acute rejection after liver transplantation: experiment with rats].
    Shi LB; Zhang HW; Peng CH
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):942-6. PubMed ID: 17650415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
    He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
    Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis.
    Kilinc MO; Rowswell-Turner RB; Gu T; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Dec; 183(12):7656-60. PubMed ID: 19923444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells.
    Zheng G; Liu S; Wang P; Xu Y; Chen A
    Cancer Res; 2006 Jul; 66(13):6793-9. PubMed ID: 16818656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.